Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079551 | 0.83 | GAA (0.50) | HTTGAAL3MBTL1POLBCYP3A4 | |
| SCHEMBL1521469 | 0.82 | HTT (0.56) | HTTGAAL3MBTL1POLBCYP3A4 | |
| SCHEMBL12479809 | 0.80 | HTT (0.55) | HTTGAAL3MBTL1POLBCYP3A4 | |
| SCHEMBL2760498 | 0.78 | POLB (0.65) | HTTGAAL3MBTL1POLBCYP3A4 | |
| SCHEMBL18354808 | 0.78 | NPC1 (0.56) | HTTPOLBCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL16943099 | 0.76 | NPC1 (0.55) | HTTGAAPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL6419072 | 0.76 | GAA (0.62) | GAAL3MBTL1POLBCYP3A4ALDH1A1 | |
| SCHEMBL6423039 | 0.76 | GAA (0.41) | HTTGAAL3MBTL1POLBCYP3A4 | |
| SCHEMBL8657291 | 0.76 | HTT (0.57) | HTTL3MBTL1POLBCYP3A4ALDH1A1 | |
| SCHEMBL6424478 | 0.75 | GAA (0.40) | GAAL3MBTL1POLBCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119246-A1 | 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119246-A1 | 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction | HTR2C, GPR119, HTR2B | HTT 3947/4885GAA 4200/4885L3MBTL1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.